{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.5","upperLimit":"55.2","value":"48.8"},{"groupId":"OG001","lowerLimit":"48.1","upperLimit":"60.4","value":"54.3"},{"groupId":"OG002","lowerLimit":"48.0","upperLimit":"60.4","value":"54.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"254"},{"groupId":"OG002","value":"257"}],"units":"Participants"}],"description":"This analysis includes all randomized subjects from BMT CTN 0702, classified by their treatment assignment (intention-to-treat). Disease progression is defined as progression of multiple myeloma, including one or more of the following:\n\n* Reappearance of serum monoclonal paraprotein at a level \\>= 0.5 g/dL\n* 24-hour urine protein electrophoresis of at least 200mg paraprotein/24 hours\n* Abnormal free light chain levels of \\>10 mg/dl, only in patients without measurable paraprotein in serum and urine\n* At least 10% plasma cells in a bone marrow aspirate or trephine biopsy\n* Definite increase in the size of existing bone lesions or soft tissue plasmacytomas\n* Development of new bone lesions or soft tissue plasmacytomas\n* Development of hypercalcemia (corrected serum Ca \\>11.5 mg/dL or \\>2.8 mmol/L) not attributable to other causes\n\nTo account for loss to follow-up, the Aalen-Johansen estimator was used to estimate the cumulative incidence of progression during the follow-up period.","dispersionType":"95% Confidence Interval","groups":[{"description":"Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance\n\nLenalidomide: In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.","id":"OG000","title":"Tandem Auto Transplant"},{"description":"Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance\n\nLenalidomide: In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.","id":"OG001","title":"RVD Consolidation"},{"description":"Initial autologous transplant followed by lenalidomide maintenance\n\nLenalidomide: In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.","id":"OG002","title":"Lenalidomide Maintenance"}],"paramType":"NUMBER","populationDescription":"All 754 randomized BMT CTN 0702 participants are included in this analysis","reportingStatus":"POSTED","timeFrame":"5 years post-randomization in BMT CTN 0702","title":"Percentage of Participants With Disease Progression","type":"SECONDARY","unitOfMeasure":"percentage of participants"}